Research progress in ocular surface reconstruction

doi:10.3877/cma.j.issn.2095-2007.2024.03.010

Abstract

Abstract:

The ocular surface is a complex structure that maintains the integrity of the cornea through a homeostatic mechanism. When the ocular surface changes due to disease, its homeostasis is lost, leading to discomfort, corneal opacity, and visual impairment. The traditional treatment methods for ocular surface diseases mainly include eye drops or transplantation surgery, while ocular surface reconstruction therapy repairs damaged ocular surfaces by stimulating the proliferation of ocular surface cells, maintaining ocular surface homeostasis, and restoring ocular surface function. It has been demonstrated that promoting corneal tissue regeneration and improving tear film stability to restore damaged ocular surfaces can improve the quality of life of patients with ocular surface, which has long-term advantages over traditional methods in treating ocular surface diseases. The new progress in ocular surface reconstruction methods based on common ocular surface diseases such as limbal stem cell deficiency, neurotrophic keratopathy, dry eye disease, and pterygium were reviewed in this paper.

Key words: Ocular surface, Ocular surface reconstruction, Limbal stem cell deficiency, Neurotrophic keratopathy, Dry eye disease, Pterygium

Han Liu, Lanyue Zhang, Qiang Shen. Research progress in ocular surface reconstruction[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2024, 14(03): 182-186.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2024.03.010

https://zhykyxzz.cma-cmc.com.cn/EN/Y2024/V14/I03/182

References 50

[1]	Parikh AO, Conger JR, Li J, et al. A review of current uses of amniotic membrane transplantation in ophthalmic plastic and reconstructive surgery[J]. Ophthalmic Plast Reconstr Surg, 2024, 40(2): 134－149.
[2]	Kalirajan C, Dukle A, Nathanael AJ, et al. A Critical review on polymeric biomaterials for biomedical applications[J]. Polymers (Basel), 2021, 13(17): 3015.
[3]	Amador C, Shah R, Ghiam S, et al. Gene therapy in the anterior eye segment[J]. Curr Gene Ther. 2022, 22(2): 104－131.
[4]	Tonti E, Manco GA, Spadea L, et al. Focus on limbal stem cell deficiency and limbal cell transplantation[J]. World J Transplant, 2023, 13(6): 321－330.
[5]	Kate A, Basu S. A review of the diagnosis and treatment of limbal stem cell deficiency[J]. Front Med, 2022, 9: 836009.
[6]	Atalay E, Altuğ B, Çalᶊkan ME, et al. Animal models for limbal stem cell deficiency: a critical narrative literature review [J]. Ophthalmol Ther, 2024, 13(3): 671－696.
[7]	Ganger A, Singh A, Kalaivani M, et al. Outcomes of surgical interventions for the treatment of limbal stem cell deficiency[J]. Indian J Med Res, 2021, 154(1): 51－61.
[8]	Jurkunas U, Johns L, Armant M. Cultivated autologous limbal epithelial cell transplantation: new frontier in the treatment of limbal stem cell deficiency[J]. Am J Ophthalmol, 2022, 239: 244－268.
[9]	Cabral JV, Jackson CJ, Utheim TP, et al. Ex vivo cultivated oral mucosal epithelial cell transplantation for limbal stem cell deficiency: a review[J]. Stem Cell Res Ther, 2020, 11(1): 301.
[10]	Figueiredo FC, Glanville JM, Arber M, et al. A systematic review of cellular therapies for the treatment of limbal stem cell deficiency affecting one or both eyes[J]. Ocul Surf, 2021, 20: 48－61.
[11]	da－Mata－Martins－TM, da－Silva－Cunha P, Rodrigues MA, et al. Epithelial basement membrane of human decellularized cornea as a suitable substrate for differentiation of embryonic stem cells into corneal epithelial－like cells[J]. Mater Sci Eng C Mater Biol Appl, 2020, 116: 111215.
[12]	He J, Ou S, Ren J, et al. Tissue engineered corneal epithelium derived from clinical－grade human embryonic stem cells[J]. Ocul Surf. 2020, 18(4): 672－680.
[13]	寿天.人类胚胎干细胞法律规制的路径研究[J]. 医学与法学，2024，16(2)：81－85.
[14]	Calonge M, Nieto－Miguel T, de－la－Mata A, et al. Goals and challenges of stem cell－based therapy for corneal blindness due to limbal deficiency[J]. Pharmaceutics, 2021, 13(9): 1483.
[15]	Masood F, Chang JH, Akbar A, et al. Therapeutic strategies for restoring perturbed corneal epithelial homeostasis in limbal stem cell deficiency: current trends and future directions[J]. Cells, 2022, 11(20): 3247.
[16]	Zhang N, Luo X, Zhang S, et al. Subconjunctival injection of tumor necrosis factor－α pre－stimulated bone marrow－derived mesenchymal stem cells enhances anti－inflammation and anti－fibrosis in ocular alkali burns[J]. Graefes Arch Clin Exp Ophthalmol, 2021, 259(4): 929－940.
[17]	Xiao YT, Xie HT, Liu X, et al. Subconjunctival injection of transdifferentiated oral mucosal epithelial cells for limbal stem cell deficiency in rats[J]. J Histochem Cytochem, 2021, 69(3): 177－190.
[18]	Galindo S, de－la－Mata A, López－Paniagua M, et al. Subconjunctival injection of mesenchymal stem cells for corneal failure due to limbal stem cell deficiency: state of the art[J]. Stem Cell Res Ther, 2021, 12(1): 60.
[19]	Joiner D, Steinberg Y, Kang JJ. Umbilical cord graft for refractory neurotrophic keratopathy[J]. Cornea, 2023, 2(10): 1263－1267.
[20]	苏岱，张嘉莹，李瑾. 角膜知觉重建治疗神经营养性角膜病变的研究进展[J]. 中华眼科杂志，2023，59(4)：313－320.
[21]	徐睿，李双双，韩园，等．角膜痛机制的研究进展[J].复旦学报(医学版)，2021，48(4)：541－544.
[22]	Roumeau S, Dutheil F, Sapin V, et al. Efficacy of treatments for neurotrophic keratopathy: a systematic review and meta－analysis[J]. Graefes Arch Clin Exp Ophthalmol, 2022, 260(8): 2623－2637.
[23]	Deeks ED, Lamb YN. Cenegermin: A review in neurotrophic keratitis[J]. Drugs. 2020, 80(5): 489－494.
[24]	Yavuz－Saricay L, Bayraktutar BN, Lilley J, et al. Efficacy of recombinant human nerve growth factor in stage 1 neurotrophic keratopathy[J]. Ophthalmology, 2022, 129(12): 1448－1450.
[25]	Trinh T, Mimouni M, Santaella G, et al. Surgical management of the ocular surface in neurotrophic keratopathy: amniotic membrane, conjunctival grafts, lid surgery, and neurotization[J]. Eye Contact Lens, 2021, 47(3): 149－153.
[26]	Zhou TE, Robert MC. Comparing prokera with amniotic membrane transplantation: indications, Outcomes, and Costs[J]. Cornea, 2022, 41(7): 840－844.
[27]	Liu CY, Arteaga AC, Fung SE, et al. Corneal neurotization for neurotrophic keratopathy: Review of surgical techniques and outcomes[J]. Ocul Surf, 2021, 20: 163－172.
[28]	邵毅，胡瑾瑜，应平. 干眼炎症诊疗规范：2023欧洲专家共识解读[J].眼科新进展，2024, 44(2)：85－88.
[29]	林琳，冯云，傅瑶，等. 眼表微环境与泪膜稳态对视觉质量影响的新认识[J]. 中华眼视光学与视觉科学杂志，2022，24(12)：881－887.
[30]	Kumar NR, Praveen M, Narasimhan R, et al. Tear biomarkers in dry eye disease: Progress in the last decade[J]. Indian J Ophthalmol, 2023, 71(4): 1190－1202.
[31]	Borgia A, Raimondi R, Fossati G, et al. Device－based therapies as a boost of conventional treatment in dry eye disease[J]. Expert Rev Ophthalmol, 2022, 17: 387－393.
[32]	Vazirani J, Sridhar U, Gokhale N, et al. Autologous serum eye drops in dry eye disease: Preferred practice pattern guidelines[J]. Indian J Ophthalmol, 2023, 71(4): 1357－1363.
[33]	Watson SL, Secker GA, Daniels JT. The effect of therapeutic human serum drops on corneal stromal wound－healing activity[J]. Curr Eye Res, 2008, 33(8): 641－52.
[34]	van－der－Meer PF, Verbakel SK, Honohan Á，et al. Allogeneic and autologous serum eye drops: a pilot double－blind randomized crossover trial[J]. Acta Ophthalmol, 2021, 99(8): 837－842.
[35]	Maharajan N, Cho GW, Choi JH, et al. Regenerative therapy using umbilical cord serum[J]. In Vivo, 2021, 35(2): 699－705.
[36]	Coco G, Piccotti G, Romano V, et al. Cenegermin for the treatment of dry eye disease[J]. Drugs Today (Barc), 2023, 59(3): 113－123.
[37]	王宇珊，郑晓汾，于花，等．翼状胬肉患者术中角膜、结膜缺损面积与其术后干眼相关性的临床研究[J/OL].中华眼科医学杂志(电子版)，2023，13(6)：344－349.
[38]	Kasetsuwan N, Bhattarakosol P, Reinprayoon U, et al. Prevalence of human papillomavirus genotypes in pterygia from thai individuals [J]. Ophthalmic Epidemiol, 2022, 29(1): 85－90.
[39]	Ghiasian L, Samavat B, Hadi Y, et al. Recurrent pterygium: a review[J]. J Curr Ophthalmol, 2022, 33(4): 367－378.
[40]	Sabater－Cruz N, Dotti－Boada M, Rios J, et al. Postoperative treatment compliance rate and complications with two different protocols after pterygium excision and conjunctival autografting[J]. Eur J Ophthalmol, 2021, 31(3): 932－937.
[41]	Adriano L, Persona ELS, Persona IGS, et al. Correlation between the presumed pterygium with dry eye and with systemic and ocular risk factors[J]. Arq Bras Oftalmol, 2021, 85(2): 136－143.
[42]	Ting DSJ, Liu YC, Lee YF, et al. Cosmetic outcome of femtosecond laser－assisted pterygium surgery[J]. Eye Vis (Lond), 2021, 8(1): 7.
[43]	Alsarhani W, Alshahrani S, Showail M, et al. Characteristics and recurrence of pterygium in Saudi Arabia: a single center study with a long follow－up[J]. BMC Ophthalmol, 2021, 21(1): 207.
[44]	Crespo MA, Rapuano CJ, Syed ZA. Applications of mitomycin c in cornea and external disease[J]. Turk J Ophthalmol, 2023, 53(3): 175－182.
[45]	Lee BWH, Sidhu AS, Francis IC, et al. 5－Fluorouracil in primary, impending recurrent and recurrent pterygium: Systematic review of the efficacy and safety of a surgical adjuvant and intralesional antimetabolite[J]. Ocul Surf, 2022, 26: 128－141.
[46]	Baheran SS, Alany RG, Schwikkard S, et al. Pharmacological treatment strategies of pterygium: Drugs, biologics, and novel natural products[J]. Drug Discov Today, 2023, 28(1): 103416.
[47]	Posarelli M, Romano D, Tucci D, et al. Ocular－surface regeneration therapies for eye disorders: the state of the art[J]. BioTech (Basel), 2023, 12(2): 48.
[48]	Palewski M, Budnik A, Konopińska J. Evaluating the efficacy and safety of different pterygium surgeries: a review of the literature[J]. J Environ Res Public Health, 2022, 19(18): 11357.
[49]	Karam M, Alsaif A, Aldubaikhi A, et al. The use of fibrin glue in pterygium surgery with amniotic membrane transplantation: Systematic review and meta－analysis[J]. Saudi J Ophthalmol, 2023, 37(2): 83－89.
[50]	Mai W, Chen M, Huang M, et al. Targeting platelet－derived growth factor receptor β inhibits the proliferation and motility of human pterygial fibroblasts[J]. Expert Opin Ther Targets, 2019, 23(9): 805－817.

Please choose a citation manager

Content to export